Literature DB >> 18230923

Aggressive management of shunt infection: combined intravenous and intraventricular antibiotic therapy for twelve or less days.

Hector E James1, John S Bradley.   

Abstract

OBJECTIVE: This report is limited to patients with a single cerebrospinal fluid (CSF) shunt infected by a single organism, and compares two treatment protocols.
METHODS: In the initial protocol (1975-1991), patients underwent removal of the shunt system and received intravenous and intraventricular antibiotics. Intraventricular antibiotics were administered twice daily to those with external ventricular drainage. When CSF was cultured 48 h off all antibiotics and found to be sterile at 24 h of incubation, a new shunt was inserted. Follow-up CSF cultures were obtained in all patients between 1-6 months following placement of the new shunt.
RESULTS: There were 25 patients (ages 1 month to 16 years; mean +/- SD: 23 +/- 4.0 months). CSF obtained from the shunt yielded the following: Staphylococcus epidermidis (19), Staphylococcus aureus (2), Streptococcus species (2), Serratia marcescens (1), and Propionebacterium species (1). The duration of intravenous antibiotics was 7-12 days (mean +/- SD: 9.7 +/- 1.3 days), and intraventricular antibiotic therapy was 6.2 +/- 1.7 days. Total hospital stay was 15.2 +/- 2.3 days. The follow-up period was 7.7 +/- 3.6 years. Following the initial protocol in another 15 patients (1992-2004), the treatment regime was modified in that intraventricular antibiotics were administered once daily in patients with external ventricular drainage, and the CSF was cultured at 24 h off antibiotics, instead of 48 h. Results were similar to the initial protocol with respect to days of antibiotic therapy and hospital stay.
CONCLUSION: Based on our retrospective nonrandomized series, we believe patients with a single shunt and noncompartmentalized hydrocephalus can be successfully treated without a prolonged antibiotic course and lengthy hospital stay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230923     DOI: 10.1159/000113111

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  7 in total

1.  Microbiology and treatment of cerebrospinal fluid shunt infections in children.

Authors:  Daniel J Adams; Michael Rajnik
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

2.  The role of intraventricular antibiotic therapy in the treatment of ventriculo-peritoneal shunt infection in children.

Authors:  Ayse Sahin; Nazan Dalgic; Mustafa Kilic; Pinar Kirgiz; M Kemal Kanik; Ersoy Oz; Adem Yilmaz
Journal:  Childs Nerv Syst       Date:  2021-03-17       Impact factor: 1.475

Review 3.  Antimicrobial treatment options for neurosurgical ventricular shunt infections in children from 1993 to 2012: a systematic review.

Authors:  Richard J Drew; Theresa S Cole; Maggie K Lee; Stéphane Paulus; Conor L Mallucci; Andrew Riordan
Journal:  Childs Nerv Syst       Date:  2013-12-10       Impact factor: 1.475

4.  Neuroendoscopic lavage for the treatment of CSF infection with hydrocephalus in children.

Authors:  C Gaderer; A Schaumann; M Schulz; U W Thomale
Journal:  Childs Nerv Syst       Date:  2018-07-11       Impact factor: 1.475

5.  Treatment strategies for cerebrospinal shunt infections: a systematic review of observational studies.

Authors:  Joan L Robinson; Dolores Freire; Liza Bialy
Journal:  BMJ Open       Date:  2020-12-10       Impact factor: 2.692

6.  Systematic Review and Meta-Analysis of Antibiotic-Impregnated Shunt Catheters on Anti-Infective Effect of Hydrocephalus Shunt.

Authors:  Wen-Xiu Zhou; Wen-Bo Hou; Chao Zhou; Yu-Xia Yin; Shou-Tao Lu; Guang Liu; Yi Fang; Jian-Wen Li; Yan Wang; Ai-Hua Liu; Hai-Jun Zhang
Journal:  J Korean Neurosurg Soc       Date:  2021-01-29

Review 7.  Evaluation of the ventriculocholecystic shunt-an overview of present practice in adult and pediatric hydrocephalus.

Authors:  Cezar Octavian Morosanu; Adelina Priscu; Ioan Stefan Florian
Journal:  Neurosurg Rev       Date:  2021-01-22       Impact factor: 3.042

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.